Applications of Mass Spectrometry Imaging for Safety Evaluation
Mass spectrometry imaging (MSI) was first derived from techniques used in physics, which were then incorporated into chemistry followed by application in biology. Developed over 50 years ago, and with different principles to detect and map compounds on a sample surface, MSI supports modern biology questions by detecting biological compounds within tissue sections. MALDI (matrix-assisted laser desorption/ionization) imaging trend analysis in this field shows an important increase in the number of publications since 2005, especially with the development of the MALDI imaging technique and its applications in biomarker discovery and drug distribution. With recent improvements of statistical tools, absolute and relative quantification protocols, as well as quality and reproducibility evaluations, MALDI imaging has become one of the most reliable MSI techniques to support drug discovery and development phases. MSI allows to potentially address important questions in drug development such as “What is the localization of the drug and its metabolites in the tissues?”, “What is the pharmacological effect of the drug in this particular region of interest?”, or “Is the drug and its metabolites related to an atypical finding?” However, prior to addressing these questions using MSI techniques, expertise needs to be developed to become proficient at histological procedures (tissue preparation with frozen of fixed tissues), analytical chemistry, matrix application, instrumentation, informatics, and mathematics for data analysis and interpretation.
Key wordsMALDI Mass spectrometry imaging (MSI) Label-free Staining Tissue distribution
The authors would like to thank Juliette Masure for the technical support and Stefan Linehan for his comments that greatly improved the manuscript.
- 5.Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I (2007) Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 6(11):4127–4134CrossRefPubMedGoogle Scholar
- 13.Bonnel D, Longuespee R, Franck J, Roudbaraki M, Gosset P, Day R, Salzet M, Fournier I (2011) Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Anal Bioanal Chem 401(1):149–165CrossRefPubMedGoogle Scholar
- 15.Brignole-Baudouin F, Desbenoit N, Hamm G, Liang H, Both J-P, Brunelle A, Fournier I, Guerineau V, Legouffe R, Stauber J, Touboul D, Wisztorski M, Salzet M, Laprevote O, Baudouin C (2012) A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an Experimental Study in Rabbits. PLoS One 7(11):e50180CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Navis AC, Niclou SP, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers RA, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden CJ, Wesseling P, Leenders WP (2013) Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG. Acta Neuropathol Commun 1:18CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Miyamoto S, Hsu C-C, Hamm G, Darshi M, Diamond-Stanic M, Declèves A-E, Slater L, Pennathur S, Stauber J, Dorrestein PC, Sharma K (2016) Mass spectrometry imaging reveals elevated glomerular ATP/AMP in diabetes/obesity and identifies sphingomyelin as a possible mediator. EBioMedicine 7:121–134CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Goodwin RJA, Iverson SL, Andren PE (2012) The significance of ambient-temperature on pharmaceutical and endogenous compound abundance and distribution in tissues sections when analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging. Rapid Commun Mass Spec 26(5):494–498CrossRefGoogle Scholar